News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
The company has reported standalone financial results for the period ended December 31, 2021.
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
New instrument helps maximize lab productivity and extends FTIR to large, heavy samples
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
The target demographic will be those between the ages of 30 and 65 years
It has signed an MoU with Plan India to expand its reach to Karnataka
The objective behind introducing this extraordinary digital campaign is to spread awareness among Gen X and Z for the need of breast self-examination
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
Unlike “Fast PCR” platforms - which uses LAMP/Isothermal technology and not gold standard RT-PCR - CoviSwift has high accuracy and sensitivity and is suitable for airports and hospitals
Subscribe To Our Newsletter & Stay Updated
